+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma



68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma



Indian Journal of Nuclear Medicine 32(2): 164




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059297350

Download citation: RISBibTeXText

PMID: 28533656


Related references

Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. Journal of Nuclear Medicine 46(5): 763-769, 2005

PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. Journal of Nuclear Medicine 42(7): 1053-1056, 2001

Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors. Clinical Nuclear Medicine 41(6): 447-453, 2016

Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. Clinical Oncology ) 12(2): 121-123, 2000

Safety assessment of a formulation for 68Ga-DOTATOC (68Ga-edotreotide or 68Ga-DOTA0-Tyr3-octreotide) preparation: Case studies in rats and rabbits. Journal of Pharmacological and Toxicological Methods 81: 379-380, 2016

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Annals of Oncology 12(7): 941-945, 2001

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nuclear Medicine Communications 29(3): 283-290, 2008

2269 [177Lu-Dota]-D-Phe1-Tyr3-octreotide (177Lu-Dotatoc) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: A retrospective phase Ii study of efficacy and safety. European Journal of Cancer 51: S422-S423, 2015

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. European Journal of Nuclear Medicine 28(4): 426-434, 2001

Personnel exposure in labelling and administration of (177)Lu-DOTA-D-Phe1-Tyr3-octreotide. Nuclear Medicine Communications 32(10): 947-953, 2011

Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. Nuclear Medicine Communications 30(2): 176-182, 2009

Receptor-mediated radiotherapy with90Y-DOTA-D-Phe1-Tyr3-octreotide. European Journal of Nuclear Medicine and Molecular Imaging 28(4): 426-434, 2001

Kinetic analysis of 68Ga-DOTA0-D PHE1-TYR3-octreotide in untreated meningiomas. Journal of Nuclear Medicine 44(5 Suppl.): 244P, 2003

68Ga-DOTA0-D Phe1-Tyr3-octreotide kinetics in the follow-up of irradiated meningiomas. Journal of Nuclear Medicine 44(5 Suppl.): 117P, 2003

68Ga-DOTA0-D PHE1-TYR3-octreotide A new PET-ligand for imaging somatostatin receptors in meningiomas. Journal of Nuclear Medicine 42(5 Suppl.): 67P, 2001